CAPTRUST FINANCIAL ADVISORS

Position in EDIT — Editas Medicine, Inc.

CIK 1512024 RALEIGH, NC

Position in EDIT

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$69,036

+$36,718 QoQ

Shares Held

27,950

+77.3% QoQ

Ownership

0.029%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2020

14 quarters on record

Voting authority Sole 27.813953488372096.ToString("F0")% Shared 0.ToString("F0")% None 72.18604651162791.ToString("F0")%

Healthcare · as of Mar 31, 2026

CAPTRUST FINANCIAL ADVISORS holds $130,226,430 across 94 Biotechnology names. EDIT ranks #73 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	38,502	$29,748,185
2	VRTX	Vertex Pharmaceuticals Inc / Ma	32,092	$14,330,361
3	EXEL	Exelixis, Inc.	312,296	$13,394,375
4	HALO	Halozyme Therapeutics, Inc.	121,088	$7,825,917
5	CELC	Celcuity Inc.	61,068	$6,970,301
6	RPRX	Royalty Pharma plc	143,760	$6,896,167
7	LGND	Ligand Pharmaceuticals Inc	29,900	$5,969,535
8	INCY	Incyte Corp	53,555	$5,040,596

14 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$69,036	27,950	+77.3%	Shares	Sole	2026-05-15
2025-12-31	$32,318	15,765	-0.1%	Shares	Sole	2026-02-17
2025-09-30	$54,735	15,774	+33.7%	Shares	Sole	2025-11-19
2025-06-30	$25,964	11,802	+618.3%	Shares	Sole	2025-08-15
2022-06-30	$19,436	1,643	-29.6%	Shares	Sole	2022-08-23
2022-03-31	$44,392	2,334	-71.8%	Shares	Sole	2022-05-16
2021-12-31	$219,754	8,277	-70.1%	Shares	Sole	2022-02-14
2021-09-30	$1,138,573	27,716	+15.7%	Shares	Sole	2021-11-16
2021-06-30	$1,357,037	23,959	+2.8%	Shares	Sole	2021-08-16
2021-03-31	$978,600	23,300	+0.7%	Shares	Sole	2021-05-17
2020-12-31	$1,621,504	23,128	+41.7%	Shares	Sole	2021-02-16
2020-09-30	$457,939	16,320	+127.9%	Shares	Sole	2020-11-17
2020-06-30	$211,792	7,160	-27.5%	Shares	Sole	2020-08-14
2020-03-31	$195,920	9,880	—	Shares	Sole	2020-05-15
No filing history on record for this holder in this stock.